Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

CIMAvax-EGF: Toward long-term survival of advanced NSCLC.

Saavedra D, Neninger E, Rodriguez C, Viada C, Mazorra Z, Lage A, Crombet T.

Semin Oncol. 2018 Jan;45(1-2):34-40. doi: 10.1053/j.seminoncol.2018.04.009. Epub 2018 May 1. Review.

PMID:
30318082
2.

Nimotuzumab: beyond the EGFR signaling cascade inhibition.

Mazorra Z, Chao L, Lavastida A, Sanchez B, Ramos M, Iznaga N, Crombet T.

Semin Oncol. 2018 Jan;45(1-2):18-26. doi: 10.1053/j.seminoncol.2018.04.008. Epub 2018 May 2. Review.

PMID:
30318080
3.

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients.

Mazorra Z, Lavastida A, Concha-Benavente F, Valdés A, Srivastava RM, García-Bates TM, Hechavarría E, González Z, González A, Lugiollo M, Cuevas I, Frómeta C, Mestre BF, Barroso MC, Crombet T, Ferris RL.

Front Pharmacol. 2017 Jun 19;8:382. doi: 10.3389/fphar.2017.00382. eCollection 2017.

4.

Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy.

Valdes-Zayas A, Gonzalez Z, Mulens V, Vega AM, Perez K, Lorenzo-Luaces P, Rubio MC, Estevez A, Curbelo I, Fernandez LE, Crombet T, Mazorra Z.

J Immunother. 2017 Oct;40(8):289-301. doi: 10.1097/CJI.0000000000000175.

PMID:
28604556
5.

Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.

Caballero I, Aira LE, Lavastida A, Popa X, Rivero J, González J, Mesa M, González N, Coba K, Lorenzo-Luaces P, Wilkinson B, Santiesteban Y, Santiesteban Y, Troche M, Suarez E, Crombet T, Sánchez B, Casacó A, Macías A, Mazorra Z.

Front Pharmacol. 2017 May 10;8:263. doi: 10.3389/fphar.2017.00263. eCollection 2017.

6.

P2.34: Vaxira and CIMAvax-EGF Therapeutic Vaccines Combination in the Advanced NSCLC Treatment: Track: Immunotherapy.

Macias AE, Ortiz R, Santiesteban E, Popa X, Zayas A, Mazorra Z, Mendoza I, Garcia E, Gomez R, Crombet T.

J Thorac Oncol. 2016 Oct;11(10S):S236-S237. doi: 10.1016/j.jtho.2016.08.105. Epub 2016 Sep 22. No abstract available.

7.

A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.

Rodriguez PC, Popa X, Martínez O, Mendoza S, Santiesteban E, Crespo T, Amador RM, Fleytas R, Acosta SC, Otero Y, Romero GN, de la Torre A, Cala M, Arzuaga L, Vello L, Reyes D, Futiel N, Sabates T, Catala M, Flores YI, Garcia B, Viada C, Lorenzo-Luaces P, Marrero MA, Alonso L, Parra J, Aguilera N, Pomares Y, Sierra P, Rodríguez G, Mazorra Z, Lage A, Crombet T, Neninger E.

Clin Cancer Res. 2016 Aug 1;22(15):3782-90. doi: 10.1158/1078-0432.CCR-15-0855. Epub 2016 Feb 29.

8.

Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients.

Saavedra D, García B, Lorenzo-Luaces P, González A, Popa X, Fuentes KP, Mazorra Z, Crombet T, Neninger E, Lage A.

Cancer Immunol Immunother. 2016 Jan;65(1):37-45. doi: 10.1007/s00262-015-1773-6. Epub 2015 Nov 20.

PMID:
26589409
9.

Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

Aira LE, Hernández P, Prada D, Chico A, Gómez JA, González Z, Fuentes K, Viada C, Mazorra Z.

MAbs. 2016;8(1):187-95. doi: 10.1080/19420862.2015.1105416. Epub 2015 Oct 15.

10.

A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.

Alfonso S, Valdés-Zayas A, Santiesteban ER, Flores YI, Areces F, Hernández M, Viada CE, Mendoza IC, Guerra PP, García E, Ortiz RA, de la Torre AV, Cepeda M, Pérez K, Chong E, Hernández AM, Toledo D, González Z, Mazorra Z, Crombet T, Pérez R, Vázquez AM, Macías AE.

Clin Cancer Res. 2014 Jul 15;20(14):3660-71. doi: 10.1158/1078-0432.CCR-13-1674. Epub 2014 May 1.

11.

Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.

Aira LE, López-Requena A, Fuentes D, Sánchez L, Pérez T, Urquiza A, Bautista H, Falcón L, Hernández P, Mazorra Z.

MAbs. 2014 May-Jun;6(3):783-93. doi: 10.4161/mabs.28376. Epub 2014 Mar 4.

12.

Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients.

Mulens V, de la Torre A, Marinello P, Rodríguez R, Cardoso J, Díaz R, O'Farrill M, Macias A, Viada C, Saurez G, Carr A, Crombet T, Mazorra Z, Perez R, Fernandez LE.

Hum Vaccin. 2010 Sep 14;6(9). doi: 10.4161.hv.6.9.12571. Epub 2010 Sep 14.

PMID:
20855939
13.

Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer.

Neninger E, Verdecia BG, Crombet T, Viada C, Pereda S, Leonard I, Mazorra Z, Fleites G, González M, Wilkinson B, González G, Lage A.

J Immunother. 2009 Jan;32(1):92-9. doi: 10.1097/CJI.0b013e31818fe167.

PMID:
19307998
14.

Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge.

Mazorra Z, Mesa C, Fernández A, Fernández LE.

Cancer Immunol Immunother. 2008 Dec;57(12):1771-80. doi: 10.1007/s00262-008-0503-8. Epub 2008 Mar 20.

PMID:
18351335
15.

Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.

García B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, González G, Mazorra Z, Lage A, Crombet T.

Clin Cancer Res. 2008 Feb 1;14(3):840-6. doi: 10.1158/1078-0432.CCR-07-1050.

16.

Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.

Gabri MR, Mazorra Z, Ripoll GV, Mesa C, Fernandez LE, Gomez DE, Alonso DF.

Clin Cancer Res. 2006 Dec 1;12(23):7092-8.

17.

Bacterial infections promote T cell recognition of self-glycolipids.

De Libero G, Moran AP, Gober HJ, Rossy E, Shamshiev A, Chelnokova O, Mazorra Z, Vendetti S, Sacchi A, Prendergast MM, Sansano S, Tonevitsky A, Landmann R, Mori L.

Immunity. 2005 Jun;22(6):763-72.

18.

Diacylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with Mycobacterium tuberculosis.

Gilleron M, Stenger S, Mazorra Z, Wittke F, Mariotti S, Böhmer G, Prandi J, Mori L, Puzo G, De Libero G.

J Exp Med. 2004 Mar 1;199(5):649-59. Epub 2004 Feb 23.

19.

A new aspect in glycolipid biology: glycosphingolipids as antigens recognized by T lymphocytes.

De Libero G, Donda A, Gober HJ, Manolova V, Mazorra Z, Shamshiev A, Mori L.

Neurochem Res. 2002 Aug;27(7-8):675-85. Review.

PMID:
12374202
20.

Presentation of the same glycolipid by different CD1 molecules.

Shamshiev A, Gober HJ, Donda A, Mazorra Z, Mori L, De Libero G.

J Exp Med. 2002 Apr 15;195(8):1013-21.

21.

A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.

Carr A, Mazorra Z, Alonso DF, Mesa C, Valiente O, Gomez DE, Perez R, Fernandez LE.

Melanoma Res. 2001 Jun;11(3):219-27.

PMID:
11468510
22.

A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors.

Carr A, Mullet A, Mazorra Z, Vázquez AM, Alfonso M, Mesa C, Rengifo E, Pérez R, Fernández LE.

Hybridoma. 2000 Jun;19(3):241-7.

PMID:
10952412

Supplemental Content

Loading ...
Support Center